Search research articles
Contact Us
Filters
Showing results (1-10 of 98) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2010
Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer
Christina M Annunziata, Joyce O'Shaughnessy
Cancers
|
August 25, 2019
NF-κB Signaling in Ovarian Cancer
Brittney S Harrington, Christina M Annunziata
F1000 Biology Reports
|
October 16, 2010
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
Christina M Annunziata, Susan E Bates
Seminars in Oncology
|
June 25, 2018
Proteasome inhibitors: structure and function
Ana T Nunes, Christina M Annunziata
Gynecologic Oncology
|
December 8, 2017
Clinical trials in gynecologic oncology: Past, present, and future
Christina M Annunziata, Elise C Kohn
BMC Cancer
|
April 18, 2015
Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells
Marianne K Kim, Jana James, Christina M Annunziata
Journal of Visualized Experiments : Jove
|
March 6, 2015
In vitro enrichment of ovarian cancer tumor-initiating cells
Carrie D House, Lidia Hernandez, Christina M Annunziata
Endocrine-Related Cancer
|
September 17, 2015
The role of reproductive hormones in epithelial ovarian carcinogenesis
Helen Gharwan, Kristen P Bunch, Christina M Annunziata
Frontiers in Oncology
|
February 1, 2021
Driving Immune Responses in the Ovarian Tumor Microenvironment
Franklin Ning, Christopher B Cole, Christina M Annunziata
American Journal of Therapeutics
|
January 21, 2011
Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy
James J Driscoll, Jason Burris, Christina M Annunziata
Page
of 10
Search research articles
Search
Showing results (1-10 of 98) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2010
Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer
Christina M Annunziata, Joyce O'Shaughnessy
Cancers
|
August 25, 2019
NF-κB Signaling in Ovarian Cancer
Brittney S Harrington, Christina M Annunziata
F1000 Biology Reports
|
October 16, 2010
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
Christina M Annunziata, Susan E Bates
Seminars in Oncology
|
June 25, 2018
Proteasome inhibitors: structure and function
Ana T Nunes, Christina M Annunziata
Gynecologic Oncology
|
December 8, 2017
Clinical trials in gynecologic oncology: Past, present, and future
Christina M Annunziata, Elise C Kohn
BMC Cancer
|
April 18, 2015
Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells
Marianne K Kim, Jana James, Christina M Annunziata
Journal of Visualized Experiments : Jove
|
March 6, 2015
In vitro enrichment of ovarian cancer tumor-initiating cells
Carrie D House, Lidia Hernandez, Christina M Annunziata
Endocrine-Related Cancer
|
September 17, 2015
The role of reproductive hormones in epithelial ovarian carcinogenesis
Helen Gharwan, Kristen P Bunch, Christina M Annunziata
Frontiers in Oncology
|
February 1, 2021
Driving Immune Responses in the Ovarian Tumor Microenvironment
Franklin Ning, Christopher B Cole, Christina M Annunziata
American Journal of Therapeutics
|
January 21, 2011
Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy
James J Driscoll, Jason Burris, Christina M Annunziata
Page
of 10